Regulation of Pulmonary Vascular Smooth Muscle Contractility in Pulmonary Arterial Hypertension: Implications for Therapy
There are two primary components that produce pulmonary arterial hypertension (PAH); aberrant structural changes (smooth muscle cell proliferation, smooth muscle cell hypertrophy, and the deposition of matrix proteins within the media of pulmonary arterial vessels), and excess vasoconstriction. Howe...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2017-08-01
|
| Series: | Frontiers in Physiology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fphys.2017.00614/full |
| _version_ | 1818058122809311232 |
|---|---|
| author | Melissa A. Lyle Jonathan P. Davis Frank V. Brozovich |
| author_facet | Melissa A. Lyle Jonathan P. Davis Frank V. Brozovich |
| author_sort | Melissa A. Lyle |
| collection | DOAJ |
| description | There are two primary components that produce pulmonary arterial hypertension (PAH); aberrant structural changes (smooth muscle cell proliferation, smooth muscle cell hypertrophy, and the deposition of matrix proteins within the media of pulmonary arterial vessels), and excess vasoconstriction. However, in PAH, the target and aim of all current therapeutic agents is to reduce the contractility of the pulmonary vasculature; prostaglandins, phosphodiesterase inhibitors, guanylate cyclase stimulators, endothelin antagonists, NO inhalation and Rho kinase inhibitors all influence signaling pathways in the pulmonary vascular smooth muscle to decrease vasoconstriction, and hence, pulmonary vascular resistance (PVR). This review will therefore primarily focus on discussing the signaling pathways regulating contractility in pulmonary vascular smooth muscle, the mechanism for current treatments, as well as highlighting potential targets for the development of novel therapies. |
| first_indexed | 2024-12-10T12:55:37Z |
| format | Article |
| id | doaj.art-322ddb8bd9fb4600a5c73bc0ae57df0d |
| institution | Directory Open Access Journal |
| issn | 1664-042X |
| language | English |
| last_indexed | 2024-12-10T12:55:37Z |
| publishDate | 2017-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Physiology |
| spelling | doaj.art-322ddb8bd9fb4600a5c73bc0ae57df0d2022-12-22T01:48:06ZengFrontiers Media S.A.Frontiers in Physiology1664-042X2017-08-01810.3389/fphys.2017.00614286481Regulation of Pulmonary Vascular Smooth Muscle Contractility in Pulmonary Arterial Hypertension: Implications for TherapyMelissa A. Lyle0Jonathan P. Davis1Frank V. Brozovich2Department of Cardiovascular Diseases, Mayo ClinicRochester, MN, United StatesDepartment of Physiology and Cell Biology, Ohio State UniversityColumbus, OH, United StatesDepartment of Cardiovascular Diseases, Mayo ClinicRochester, MN, United StatesThere are two primary components that produce pulmonary arterial hypertension (PAH); aberrant structural changes (smooth muscle cell proliferation, smooth muscle cell hypertrophy, and the deposition of matrix proteins within the media of pulmonary arterial vessels), and excess vasoconstriction. However, in PAH, the target and aim of all current therapeutic agents is to reduce the contractility of the pulmonary vasculature; prostaglandins, phosphodiesterase inhibitors, guanylate cyclase stimulators, endothelin antagonists, NO inhalation and Rho kinase inhibitors all influence signaling pathways in the pulmonary vascular smooth muscle to decrease vasoconstriction, and hence, pulmonary vascular resistance (PVR). This review will therefore primarily focus on discussing the signaling pathways regulating contractility in pulmonary vascular smooth muscle, the mechanism for current treatments, as well as highlighting potential targets for the development of novel therapies.http://journal.frontiersin.org/article/10.3389/fphys.2017.00614/fullcontractilityvascular diseasesvascular resistancesignaling pathwaystherapeutics |
| spellingShingle | Melissa A. Lyle Jonathan P. Davis Frank V. Brozovich Regulation of Pulmonary Vascular Smooth Muscle Contractility in Pulmonary Arterial Hypertension: Implications for Therapy Frontiers in Physiology contractility vascular diseases vascular resistance signaling pathways therapeutics |
| title | Regulation of Pulmonary Vascular Smooth Muscle Contractility in Pulmonary Arterial Hypertension: Implications for Therapy |
| title_full | Regulation of Pulmonary Vascular Smooth Muscle Contractility in Pulmonary Arterial Hypertension: Implications for Therapy |
| title_fullStr | Regulation of Pulmonary Vascular Smooth Muscle Contractility in Pulmonary Arterial Hypertension: Implications for Therapy |
| title_full_unstemmed | Regulation of Pulmonary Vascular Smooth Muscle Contractility in Pulmonary Arterial Hypertension: Implications for Therapy |
| title_short | Regulation of Pulmonary Vascular Smooth Muscle Contractility in Pulmonary Arterial Hypertension: Implications for Therapy |
| title_sort | regulation of pulmonary vascular smooth muscle contractility in pulmonary arterial hypertension implications for therapy |
| topic | contractility vascular diseases vascular resistance signaling pathways therapeutics |
| url | http://journal.frontiersin.org/article/10.3389/fphys.2017.00614/full |
| work_keys_str_mv | AT melissaalyle regulationofpulmonaryvascularsmoothmusclecontractilityinpulmonaryarterialhypertensionimplicationsfortherapy AT jonathanpdavis regulationofpulmonaryvascularsmoothmusclecontractilityinpulmonaryarterialhypertensionimplicationsfortherapy AT frankvbrozovich regulationofpulmonaryvascularsmoothmusclecontractilityinpulmonaryarterialhypertensionimplicationsfortherapy |